RET rearrangements in non-small cell lung cancer: Evolving treatment landscape and future challenges-Reference-Cited by-同舟云学术

RET rearrangements in non-small cell lung cancer: Evolving treatment landscape and future challenges

Published:2022-11 Issue:6 Volume:1877 Page:188810
ISSN:0304-419X
Container-title:Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
language:en
Short-container-title:Biochimica et Biophysica Acta (BBA) - Reviews on Cancer

Author:

Servetto Alberto,Esposito Daniela,Ferrara Roberto,Signorelli Diego,Belli Stefania,Napolitano Fabiana,Santaniello Antonio,Ciciola Paola,Formisano Luigi,Bianco Roberto

Funder

Associazione Italiana per la Ricerca sul Cancro

Publisher

Elsevier BV

Subject

Cancer Research,Genetics,Oncology

Reference155 articles.

1. Cancer statistics, 2020;Siegel;CA Cancer J. Clin.,2020

2. Global cancer statistics;Jemal;CA Cancer J. Clin.,2011

3. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Planchard;Ann. Oncol. Off. J. Eur. Soc. Med. Oncol.,2018

4. Molecular testing and targeted therapy for non-small cell lung cancer: current status and perspectives;Imyanitov;Crit. Rev. Oncol. Hematol.,2021

5. Molecular testing guideline for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the;Kalemkerian;J. Clin. Oncol.,2018

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical and molecular correlates of tumor aneuploidy in metastatic non-small cell lung cancer;Scientific Reports;2024-08-21

2. Efficacy of immunotherapy in RET fusion-positive NSCLC: A meta-analysis;Heliyon;2024-07

3. Determination of Pralsetinib in Human Plasma and Cerebrospinal Fluid for Therapeutic Drug Monitoring by Ultra-performance Liquid Chromatography-Tandem Mass Spectrometry (UPLC-MS/MS);Anti-Cancer Agents in Medicinal Chemistry;2024-07

4. NCOA4 serves as a potential prognostic biomarker and correlates with immune infiltrates in lung adenocarcinoma;2024-03-28

5. Multicenter evaluation of an automated, multiplex, RNA-based molecular assay for detection of ALK, ROS1, RET fusions and MET exon 14 skipping in NSCLC;Virchows Archiv;2024-03-16